Uppsala University Hospital

Running trials

• Recruiting

  Tau Pathology in the Brain After Hip or Knee Replacement Surgery

  NCT07871487· Uppsala University Hospital· Source

• Not yet recruiting

  GLUTAMICS III

  2024-513575-40-01· Phase 3· Region Oestergoetland· Source

• Not yet recruiting

  Sequential Treatment With Romosozumab Followed by Denosumab vs. Zoledronic Acid for Gains in HIP BMD

  NCT07772609· Phase 4· Sahlgrenska University Hospital· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of AC01 Compared to Placebo in Participants With Chronic Heart Failure

  NCT07584967· Phase 2· AnaCardio AB· Source

• Not yet recruiting

  Prophylactic Treatment of Graves Ophthalmopathy (GO) in Newly Diagnosed Graves' Disease (GD) With Atorvastatin (ATORGO)

  NCT07883356· Phase 2· Region Skane· Source

• Not yet recruiting

  Lifestyle Changes, Mushroom Supplementation, and Bupropion to Reduce Adiposity and Cardiometabolic Risk

  NCT07806279· Phase 3· Uppsala University· Source

• Recruiting

  FLAsH-IV-AML: A study evaluating the safety and effectiveness of adding hydroxyurea to treatment for adults with acute myeloid leukemia (AML) that has relapsed after treatment or has not responded to treatment

  2026-526961-76-00· Phase 1/2· Karolinska University Hospital· Source

• Recruiting

  E-Type - Early Wear of Polyethylene Liners Used in DMC

  NCT07863557· Phase 4· Uppsala University· Source

• Recruiting

  Fight Osteosarcoma Through European Research Evolving Study Platform From Diagnosis to Relapse

  NCT07871864· Phase 3· Gustave Roussy, Cancer Campus, Grand Paris· Source

• Not yet recruiting

  Remote Monitoring and Optimization of Heart Failure Therapy

  NCT07622472· Zoll Medical Corporation· Source

• Recruiting

  A multicenter, randomized, open-label, blinded-assessor, phase 4 study in patients with early rheumatoid arthritis to compare active conventional therapy versus three biologic treatments, and two de-escalation strategies in patients who respond to treatment.

  NCT01491815· Phase 4· Karolinska Institutet· Source

• Recruiting

  Group-based Emotional Awareness and Expression Therapy to Support Recovery After Acquired Brain Injury: A Clinical Development and Evaluation Study

  NCT07852936· Uppsala University· Source

• Not yet recruiting

  REcovery After Cancer Application

  NCT07642492· Karolinska Institutet· Source

• Recruiting

  Surgery for Thumb Base Osteoarthritis: Joint Replacement vs. Trapeziectomy

  NCT07569549· Uppsala University· Source

• Not yet recruiting

  Melanoma-TBK1-inhibitor enhanced Immuno Therapy with Checkpoint Inhibitors: a Phase IB/II Trial in Unresectable Stage III or Stage IV Cutaneous Melanoma

  2026-526821-16-00· Phase 1/2· Karolinska University Hospital· Source

• Recruiting

  The HIt HArd and hiT Early in Multiple Sclerosis Trial

  NCT07517185· Phase 2· Uppsala University· Source

• Recruiting

  International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)

  NCT07476729· Phase 3· Charite University, Berlin, Germany· Source

• Recruiting

  Phase 2 Randomized, Double-blind, Placebo-controlled Study of Prophylactic Tocilizumab to Prevent Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma

  2025-524793-42-00· Phase 2· Janssen Cilag International· Source

• Recruiting

  A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF

  NCT07761117· Phase 3· AstraZeneca· Source

• Recruiting

  A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.

  NCT07753993· Phase 3· AstraZeneca· Source

• Not yet recruiting

  A phase II randomised trial investigating the benefit of adjuvant immunotherapy after neoadjuvant chemoimmunotherapy for resectable NSCLC (ADIL)

  2025-524439-38-00· Phase 2· Oslo Universitetssykehus HF· Source

• Recruiting

  A study to evaluate the efficacy of oxaliplatin- or gemcitabine-based chemotherapy after allocation by standard criteria or by genetic markers in patients with resected pancreatic carcinoma

  NCT05314998· Phase 3· Universitaetsklinikum Heidelberg AöR· Source

• Recruiting

  Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation

  NCT07626411· Phase 3· Regeneron Pharmaceuticals· Source

• Not yet recruiting

  COLOVERT – Conversion therapy in colorectal cancer with peritoneal metastases not amenable to upfront cytoreductive surgery and HIPEC: a phase II “pick-the-winner” open-label randomized trial

  2026-526122-41-00· Phase 2· Uppsala University Hospital· Source

• Recruiting

  Fight Osteosarcoma Through European Research evolving study platform from diagnosis to relapse (FOSTER evolving study platform)

  2023-505575-69-01· Phase 3· Institut Gustave Roussy· Source

• Recruiting

  Personalizing chemotherapy selection after surgery for patients with stage III colorectal cancer using a blood test

  2025-521045-24-00· Phase 3· Unicancer· Source

• Recruiting

  DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

  NCT07544654· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma

  NCT07589634· Phase 2· Janssen Research & Development, LLC· Source

• Recruiting

  Crohn’s Head-to-Head Assessing Risankizumab Versus Guselkumab for One Year

  2025-521590-13-00· Phase 3· Janssen Cilag International· Source

• Recruiting

  Anti-B-cell therapy in RA-ILD

  2025-524872-51-00· Phase 4· Vaestra Goetalandsregionen· Source

• Recruiting

  A 12-Week Study of Flexilev With the OraFID Device and App in Parkinson's Patients

  NCT07839793· Phase 4· Navamedic AB· Source

• Recruiting

  Discontinuation Outcome in Multiple Myeloma after BCMA-CD3 treatment

  2025-524022-18-00· Phase 2· Vaestra Goetalandsregionen· Source

• Recruiting

  A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

  NCT07499232· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable

  NCT07430956· Phase 3· Regeneron Pharmaceuticals· Source

• Not yet recruiting

  Exploratory, non-randomized, 3-group, microdosing clinical trial to investigate Gallium-68 (68Ga) labeled Platelet-Derived Growth Factor Beta (PDGFRß) targeting Positron Emission Tomography (PET) tracer (68Ga-ATH001) binding in the lungs in healthy participants versus participants with Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD)

  2026-525309-11-00· Phase 1· Antaros Medical AB· Source

• Recruiting

  A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

  NCT07361497· Phase 3· Bristol-Myers Squibb· Source

• Recruiting

  Postoperative Acute Kidney Injury in Children Undergoing Major Non-cardiac Surgery

  NCT07351149· Uppsala University· Source

• Recruiting

  Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

  NCT07223814· Phase 3· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source

• Recruiting

  Efficacy and safety of two moisturising creams for maintenance treatment of atopic dermatitis

  2025-521620-29-01· Phase 2· Galenica AB· Source

• Recruiting

  Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis

  NCT07230288· Phase 2· AbbVie· Source

• Recruiting

  Pancreatic Neuroendocrine Tumour - Optimal Surgical Debulking or Not

  NCT07273409· Uppsala University· Source

• Recruiting

  AIDA-DEP - Accelerated Intermittent theta-burst stimulation with D-cycloserine Augmentation for DEPression - a multicenter, randomized, placebo-controlled, double-blind clinical trial

  2025-521686-27-01· Phase 2· Region Uppsala· Source

• Recruiting

  Single-Stapled Technique for Colorectal Anastomosis

  NCT07417358· Umeå University· Source

• Not yet recruiting

  Contrast Strategy In Fenestrated EndoVascular Aneurysm Repair Randomized Control Trial

  2025-521795-58-00· Phase 4· Region Skane· Source

• Recruiting

  AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer

  NCT07218809· Phase 3· AstraZeneca· Source

• Recruiting

  PIRTOBRUTINIB AND GLOFITAMAB IN MANTLE CELL LYMPHOMA

  2024-512922-27-00· Phase 2· Klinikum der Universitaet Muenchen AöR· Source

• Recruiting

  Intraperitoneal Paclitaxel and Systemic Therapy Versus Systemic Therapy Alone in Gastric Cancer Patients With Peritoneal Metastasis

  NCT07304271· Phase 3· Magnus Nilsson· Source

• Recruiting

  The IPa-Gastric trial: Comparing Intraperitoneal Paclitaxel and Systemic Therapy versus Systemic Therapy alone in Gastric Cancer Patients with Peritoneal Metastasis

  2024-514879-17-00· Phase 3· Karolinska University Hospital· Source

• Active, not recruiting

  A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

  NCT07076121· Phase 2/3· Bristol-Myers Squibb· Source

• Recruiting

  A First-in-Human Phase 1 Safety and Biodistribution of [177Lu]Lu-ABY-271 in Subjects With HER2-positive Metastatic Breast Cancer

  NCT07081555· Phase 1· Affibody· Source

Showing 50 of 246.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers23 recruiting
• Acute myeloid leukaemia11 recruiting
• Colorectal cancer10 recruiting
• Prostate cancer10 recruiting
• Atrial fibrillation8 recruiting
• Heart failure6 recruiting
• Melanoma6 recruiting
• Metastatic breast cancer6 recruiting
• Multiple myeloma6 recruiting
• Stroke6 recruiting
• Chronic kidney disease5 recruiting
• Gastric and oesophageal cancer5 recruiting
• Sarcoma5 recruiting
• Aortic aneurysm4 recruiting
• Mantle cell lymphoma4 recruiting
• Pancreatic cancer4 recruiting
• Coronary artery disease3 recruiting
• Crohn's disease3 recruiting
• Depression3 recruiting
• Endometrial cancer3 recruiting
• High blood pressure3 recruiting
• Lung cancer3 recruiting
• Myelodysplastic syndromes3 recruiting
• Osteoarthritis3 recruiting
• Acute lymphoblastic leukaemia2 recruiting
• Chronic lymphocytic leukaemia2 recruiting
• Diffuse large B-cell lymphoma2 recruiting
• Glioblastoma2 recruiting
• Neuroendocrine tumours2 recruiting
• Ovarian cancer2 recruiting
• Rheumatoid arthritis2 recruiting
• Schizophrenia2 recruiting
• Triple-negative breast cancer2 recruiting
• Alzheimer disease1 recruiting
• ANCA-associated vasculitis1 recruiting
• Aortic stenosis1 recruiting
• Asthma1 recruiting
• Atopic dermatitis (eczema)1 recruiting
• Chronic myeloid leukaemia1 recruiting
• COPD1 recruiting
• Dermatomyositis and polymyositis (myositis)1 recruiting
• Endometriosis1 recruiting
• Epilepsy1 recruiting
• Essential tremor1 recruiting
• Follicular lymphoma1 recruiting
• Graves' disease and hyperthyroidism1 recruiting
• Hodgkin lymphoma1 recruiting
• Hydrocephalus1 recruiting
• Idiopathic pulmonary fibrosis1 recruiting
• Liver and biliary tract cancer1 recruiting
• Multiple sclerosis1 recruiting
• Neuroblastoma1 recruiting
• Obesity1 recruiting
• Osteoporosis1 recruiting
• Parkinson disease1 recruiting
• Peripheral artery disease1 recruiting
• Psoriasis1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting
• Ulcerative colitis1 recruiting

Closed trials

• Completed

  A clinical trial to learn about the effects of VHB937 in people with Alzheimer's disease

  2024-516966-12-00· Phase 2· Novartis Pharma AG· Source

• Recruiting

  A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

  NCT07253285· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Study of TAK-861 in People With Narcolepsy Type 1

  NCT06505031· Phase 3· Takeda· Source

• Active, not recruiting

  A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer

  NCT06497556· Phase 3· Hoffmann-La Roche· Source

• Completed

  A Study to Learn About How Well BAY3283142 Works and Its Safety in Participants With Chronic Kidney Disease

  NCT06522997· Phase 2· Bayer· Source

• Active, not recruiting

  A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease

  NCT06544616· Phase 2· Janssen Pharmaceutica N.V., Belgium· Source

• Active, not recruiting

  Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis

  2023-508235-31-00· Phase 3· Almirall S.A.· Source

• Active, not recruiting

  A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease

  NCT05970172· Phase 3· Astellas Pharma Global Development, Inc.· Source

• Active, not recruiting

  A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

  NCT06105632· Phase 2· Pfizer· Source

• Completed

  Levels of Inflammation in People With Cardiovascular Disease (POSEIDON)

  NCT06122961· Novo Nordisk A/S· Source

• Completed

  A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension

  NCT06034743· Phase 3· AstraZeneca· Source

• Completed

  A Study to Evaluate the Safety of KAND567, in Combination With Carboplatin Therapy, in Women With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

  NCT06087289· Phase 1/2· Novakand Pharma AB· Source

• Completed

  A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2

  NCT05737940· Phase 2· AstraZeneca· Source

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Bayer· Source

• Completed

  The Effect of Autoreactive Autoantibodies on Peripheral and Central Disease Mechanisms in Fibromyalgia.

  NCT07346950· Uppsala University· Source

• Completed

  A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolism in people with irregular and often rapid heartbeat (atrial fibrillation), and at risk for stroke

  NCT05643573· Phase 3· Bayer AG· Source

• Completed

  Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With History of Inadequate Response to Oral Preventive Medications

  NCT05518123· Phase 4· Pfizer· Source

• Completed

  A Study in Participants With Non-cirrhotic NASH With Fibrosis

  NCT05638737· Phase 2· AstraZeneca· Source

• Completed

  A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)

  NCT05508867· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

  NCT05321069· Phase 3· Boehringer Ingelheim· Source

• Completed

  A Study of Relatlimab-nivolumab Fixed-dose Combination versus Regorafenib or TAS-102 in Participants with Later-lines of Metastatic Colorectal Cancer

  NCT05328908· Phase 3· Bristol Myers Squibb International Corporation· Source

• Enrolling by invitation

  A Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and it's Effects on Symptoms in Adults With Systemic Lupus Erythematosus (SLE)

  NCT05352919· Phase 3· Biogen· Source

• Active, not recruiting

  New Clinical End-points in patients with primary Sjögren’s Syndrome: an Interventional Trial based on stratifYing patients

  NCT05113004· Phase 2· Assistance Publique Hopitaux De Paris· Source

• Completed

  Efficacy and Safety in Imlifidase Desensitized Kidney Tx Patients, Including Two Non-Comparative Reference Cohorts

  NCT05369975· Phase 3· Hansa Biopharma AB· Source

• Completed

  A study to test long-term safety of Iclepertin in people with schizophrenia who took part in a previous CONNEX study

  2024-511560-93-00· Phase 3· Boehringer Ingelheim International GmbH· Source

• Active, not recruiting

  A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria

  NCT05196035· Phase 3· Bayer· Source

• Completed

  Acetazolamide Trial in Normal Pressure Hydrocephalus

  NCT04975269· Phase 2· Uppsala University Hospital· Source

• Completed

  A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness

  NCT05014672· Phase 2· Calliditas Therapeutics Suisse SA· Source

• Completed

  A Safety Study of Lactobacillus Reuteri BGP-014 in Patients With Ulcerative Colitis

  NCT05118919· Phase 1/2· BioGaia Pharma AB· Source

• Completed

  NORDTREAT Prospective Study on Inflammatory Bowel Disease

  NCT05414578· University of Southern Denmark· Source

• Terminated

  The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis

  NCT04985968· Phase 3· InDex Pharmaceuticals· Source

• Completed

  Metformin Intervention in children and adolescents with obesity. A parallel, three arms, randomized, 6 months, multi-center study with metformin extended release (XR) plus lifestyle or metformin immediate release (IR) plus lifestyle or lifestyle alone.

  2024-517787-29-00· Phase 2· Region Uppsala· Source

• Completed

  Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-1)

  NCT04846868· Phase 3· Boehringer Ingelheim· Source

• Active, not recruiting

  A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease

  NCT04929210· Phase 4· Janssen Research & Development, LLC· Source

• Completed

  ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation

  NCT05021835· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients

  NCT04844866· Phase 2· Miltenyi Biomedicine GmbH· Source

• Active, not recruiting

  A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

  NCT04895241· Phase 3· Biogen· Source

• Completed

  A Study of the Efficacy and Safety of Frespaciguat (MK-5475) in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007)

  NCT04732221· Phase 2/3· Merck Sharp & Dohme LLC· Source

• Completed

  Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)

  NCT04564339· Phase 2· Alexion Pharmaceuticals Inc.· Source

• Terminated

  Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors

  NCT04272034· Phase 1· Incyte Corporation· Source

• Terminated

  Study to Evaluate Safety and Efficacy of IBsolvMIR in Islet Transplantation

  NCT03867851· Phase 2· TikoMed AB· Source

• Completed

  Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung Cancer

  NCT04475939· Phase 3· GlaxoSmithKline· Source

• Completed

  Observational Study To Assess The Effectiveness and Treatment Adherence Of Tofacitinib of Ulcerative Colitis In Clinical Practice In Sweden

  NCT04338204· Pfizer· Source

• Terminated

  Futibatinib in Patients With Specific FGFR Aberrations

  NCT04189445· Phase 2· Taiho Oncology, Inc.· Source

• Completed

  Study to evaluate the addition of an experimental drug, CC-90010, to the usual treatment of brain cancer after surgery

  2024-511171-15-00· Phase 1· Celgene Corp.· Source

• Completed

  Randomized Comparison of Abluminus DES+ Sirolimus-Eluting Stents Versus Everolimus-Eluting Stents in Coronary Artery Disease Patients With Diabetes Mellitus Global

  NCT04236609· Concept Medical Inc.· Source

• Completed

  Study of Radspherin® in Colorectal Carcinoma Subjects With Peritoneal Carcinomatosis Treated With HIPEC

  NCT03732781· Phase 1/2· Oncoinvent Solutions AS· Source

• Terminated

  A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205

  NCT04241068· Phase 3· Biogen· Source

• Completed

  The Impact of Gut Microbiota in Anastomoses Insufficiency After Resection and Direct Anastomosis for Colorectal Cancer.

  NCT04252560· Uppsala University Hospital· Source

• Completed

  Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients

  NCT04008706· Phase 3· AstraZeneca· Source

Showing 50 of 80.

Conditions

Diseases this institution publishes on or runs trials for.

• Neuroendocrine tumours12 works · 4 trials
• Hydrocephalus7 works · 2 trials